Orelabrutinib Combined With Pola-R-CHP Regimen for the Treatment of Untreated Non-GCB Diffuse Large B-Cell Lymphoma
Status:
RECRUITING
Trial end date:
2028-12-31
Target enrollment:
Participant gender:
Summary
Assess the preliminary efficacy and safety of orelabrutinib in combination with the Pola-R-CHP regimen for the treatment of treatment-naive Non-GCB diffuse large B-cell lymphoma.
Phase:
PHASE2
Details
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University
Collaborators:
Affiliated Hangzhou First People's Hospital Affiliated Hospital of Jiaxing University Dongyang People's Hospital Huzhou Central Hospital Ningbo People's Hospital Second Affiliated Hospital of Wenzhou Medical University Shaoxing Central Hospital Shaoxing People's Hospital Taizhou Central Hospital affiliated to Taizhou University Taizhou First People's Hospital The Central Hospital of Lishui City The People's Hospital of Quzhou The Second Affiliated Hospital of Jiaxing University Yuyao People's Hospital Zhejiang Cancer Hospital Zhuji People's hospital